Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
32/100
Microglia are central regulators of Alzheimer's disease pathogenesis, but their roles cannot be reduced to a simple protective-versus-harmful dichotomy.
Why it matters
This review discusses a proposed PU.1/CD28 regulatory axis in microglia and suggests PU.1-low CD28-positive microglia may restrain neuroinflammation and amyloid pathology. It is a conceptual review and does not demonstrate any treatment, cure or prevention for patients.
-
To determine the relationship between regional brain edema caused by anti-amyloid monoclonal antibody therapy (ARIA-E) and the degree of regional β-amyloid (Aβ) positron emission tomography (PET) signal reduction.
Why it matters
This entry only states the aim of determining the relationship between regional brain edema (ARIA-E) caused by anti-amyloid antibody therapy and the degree of regional amyloid PET signal reduction. No results or conclusions are provided in the available text, so nothing can be said about what it means for treating, curing or preventing the disease.
-
BackgroundNeighborhood disadvantage has been associated with reduced cognitive reserve, increased risk for cognitive impairment, and greater Alzheimer's disease (AD) neuropathology, with particularly pronounced effects among Black and Hispanic/Latino older adults.
Why it matters
In a diverse community sample, some Alzheimer's blood markers were linked to neighborhood disadvantage, but the patterns differed by cognitive status and race or ethnicity. This kind of study can only show associations and does not test whether changing neighborhood conditions affects Alzheimer's disease.
-
The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of AD, but is not free of challenges.
Why it matters
This consensus document from the Spanish Society of Neurology's study group addresses practical considerations for using anti-amyloid antibodies, with prescribing centre requirements and criteria for stopping treatment generating the most debate. It notes concerns about equity of access and implementation into current care if insufficient resources are allocated, and will need updating as new knowledge or drugs emerge.
-
Alzheimer disease (AD) is a neurodegenerative disorder characterized by amyloid plaque deposition, neurofibrillary tangles, and chronic neuroinflammation.
Why it matters
Nine systemic inflammatory factors were associated with increased Alzheimer's disease risk, while five circulating inflammatory factors were considered downstream consequences of the disease. These results clarify the roles of inflammatory factors such as cystatin D and monocyte chemoattractant protein-4.
-
Donanemab increased total healthcare costs ($300,689 vs. $178,121) and societal costs ($389,113 vs. $283,618) compared with standard care per capita, while improving health outcomes (4.38 vs. 4.01 QALYs) per capita.
Why it matters
Donanemab improved health outcomes compared with standard care but raised healthcare and societal costs, with cost-effectiveness ratios exceeding frequently cited Australian willingness-to-pay thresholds. It is unlikely to be cost-effective under current Australian thresholds, and health gains appeared inequitable by remoteness.
-
Sowohl in der Tau- als auch in der Amyloid-PET-Bildgebung zeigte die Quantifizierung eine gute bis exzellente Vorhersage der visuellen Beurteilung (Tau: AUC=0,86, p<0,0001; Amyloid: AUC=0,99, p<0,0001).
Why it matters
This study compared quantitative amyloid and tau PET measures with visual reading and spinal fluid biomarkers in a real-world clinical setting, finding good agreement and establishing cutoff values. It is a diagnostic validation study and does not test any treatment, cure, or prevention.
-
32/100
Using approximately 5,000 ADNI MRI images, the model achieved 97.67% accuracy, 97.73% precision, 97.67% recall, and 97.65% F1-score, with AUC values near 1.00.
Why it matters
A CNN classified AD, MCI, and cognitively normal MRI scans with 97.67% accuracy and was deployed as a web tool giving predictions in under five seconds. The authors note the need for multimodal integration and prospective clinical validation, so this is a screening feasibility tool, not a treatment or cure.
-
Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or older in the United States.
Why it matters
This article explains that amyloid-beta PET imaging can help diagnose Alzheimer disease and identify patients eligible for new anti-amyloid therapies. It is an overview of imaging's role in evaluation and treatment selection, not a study of whether any treatment cures or prevents the disease.
-
The role of noise pollution as a risk factor for Alzheimer disease (AD) is unclear, with observational studies yielding conflicting results susceptible to confounding and reverse causality.
Why it matters
This two-sample Mendelian randomization study found no evidence of a causal association between genetically predicted daytime or evening noise exposure and Alzheimer disease risk. The authors state the findings do not support a direct causal link between noise and Alzheimer disease, though indirect mechanisms through sleep disruption or cardiovascular pathways are not ruled out.
-
The use of statistical physics models to investigate real-world networks and reveal their underlying dynamics has shown promising results and acquired increasing attention.
Why it matters
Using T1-weighted MRI scans from 126 normal controls and 92 Alzheimer's patients, this study applied exponential random graph models to brain connectivity networks and reached an overall classification accuracy of 0.82±0.08. The authors say the approach could support diagnosis and help investigate disease mechanisms, but it is a diagnostic and explanatory tool, not a treatment, cure or prevention.
-
Magnetic Resonance Imaging (MRI) provides detailed structural information, while functional MRI (fMRI) captures temporal brain activity.
Why it matters
A multimodal deep learning framework combined MRI and fMRI for classifying AD, MCI, and normal cognition, and data augmentation improved stability on a small paired dataset of 29 subjects. The small sample size makes this preliminary, and it addresses diagnosis rather than treatment or cure.
-
PET imaging demonstrated high cortical brain uptake of all 3 radiotracers in Tg-ArcSwe mice.
Why it matters
In Tg-ArcSwe mice, immuno-PET with radiolabeled Lec-Fab8D3 enabled specific detection of brain Aβ pathology, with 89Zr producing the highest overall signal and 124I yielding greater regional contrast. These findings are from animal studies and concern imaging of amyloid, not treatment, cure or prevention of Alzheimer's disease.
-
Orally dosed D-AIP possessed favourable biostability, pharmacokinetics, and brain region distribution.
Why it matters
In an Alzheimer's mouse model at very early stages of amyloid deposition, orally given D-AIP targeted toxic Aβ oligomers, reduced plaque amyloid pathology and neuroinflammation, and showed no adverse effects on memory and cognition. These findings are from animal and laboratory work, so it is not yet known whether the compound would work or be safe in people.
-
Like CP2, C458 and C273 weakly inhibit mtCI, leading to AMPK activation, which triggers a neuroprotective stress response.
Why it matters
In laboratory and mouse studies, the compounds C458 and C273 weakly inhibited mitochondrial complex I, triggering a neuroprotective stress response that protected against Aβ toxicity, and chronic C458 preserved cognition in APP/PS1 mice. These findings are from in vitro and animal models, so it is not yet known whether the compounds would work or be safe in people.
-
Within around 700 new designed PROTACs, we found by computational modelling more than 25 PROTACs that were predicted to have a better ability to form ternary complexes than the previously reported PROTACs.
Why it matters
This describes computational design of PROTAC molecules intended to promote tau degradation, with predictions of good oral bioavailability and brain permeability, and notes that membrane permeability and cell model evaluations are still being performed. It is early laboratory work and does not demonstrate any treatment, cure or prevention in people.
-
In 2004, the first radiotracer that bound amyloid plaques was reported, which enabled visualization of the amount and regional distribution of amyloid plaques in the brains of living individuals via positron emission tomography (PET).
Why it matters
This review describes the development of imaging and fluid biomarkers for Alzheimer's disease over the past quarter century and their use in research, trials and clinical diagnosis. It is about biomarkers and diagnosis, not treatment, and does not demonstrate any cure or prevention.
-
Neben ihrer Wirkung auf Gewichtskontrolle und kardiometabolische Parameter könnten GLP-1RA auch die endokrine Funktion von Adipozyten sowie die chronische Inflammation bei der Adipositas und damit die Entstehung adipositasassoziierter Tumoren modulieren.
Why it matters
This German-language article discusses whether GLP-1 receptor agonists might modulate adipose tissue endocrine function and chronic inflammation in obesity, and thereby the development of obesity-associated tumors. It states that prospective studies are needed to determine the boundary between fact and fiction regarding the oncological significance of these drugs.
-
Letter in response to the article by Wang et al. recently published in Alzheimer's & Dementia (Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.
Why it matters
This is a letter commenting on a previously published study about semaglutide and first-time Alzheimer's disease diagnosis in people with type 2 diabetes. The text provided contains no findings of its own about treating, curing or preventing Alzheimer's disease.
-
According to the latest report in 2024 by the World Health Organization, based on global data from 2021, Alzheimer’s disease (AD) and other forms of dementia rank seventh among the leading causes of death worldwide, with an estimated 1.8 million deaths.
Why it matters
This review notes that no cure exists and effective treatments remain limited, with lecanemab the only fully approved drug for slowing Alzheimer's progression by clearing amyloid-beta plaques. It highlights neuroinflammatory pathways as promising targets, but these are not yet proven treatments.
-
To the Editor: We have recently highlighted the potential pitfalls of amyloid-beta (Aβ) PET, suggesting that both Aβ and tau assessments are necessary to relate clinical symptoms to Alzheimer disease (AD) pathology.1 Herein, we would like to present 3 additional cases related to the clinical practice of disease-modifying therapy (DMT) for AD.
Why it matters
Through three real-world cases, the authors argue that both amyloid-beta and tau assessments are needed to confirm that symptoms are due to Alzheimer disease pathology before starting disease-modifying therapy. They suggest this matters for ensuring appropriate use of lecanemab and donanemab, which are designed for mild cognitive impairment or mild dementia due to AD pathology.
-
Alzheimer's disease currently has no cure and is usually detected too late for interventions to be effective.
Why it matters
In cognitively normal people, this study mapped how age and APOE gene variation relate to long-range brain connections, finding that certain connections in the occipital cortex and cerebellum declined faster depending on genotype. These are possible early markers of neurodegeneration, but the work does not test any treatment or prevention.
-
BackgroundDespite dementia with Lewy bodies (DLB) being the second most common form of neurodegenerative dementia, more than 80% of DLB cases are initially misdiagnosed.
Why it matters
In a small study of 21 dementia with Lewy bodies patients and other groups, salivary pS199-tau was higher in dementia with Lewy bodies and Alzheimer's disease than in healthy controls and Parkinson's disease. This is a preliminary diagnostic study and does not test any treatment or prevention.
-
Alzheimer's Disease (AD) remains a significant global health challenge, characterized by progressive neurodegeneration and a decline in cognitive abilities such as memory and learning.
Why it matters
This review states that the cholinergic hypothesis is no longer satisfactory and that current treatments such as acetylcholinesterase inhibitors have limited efficacy, while emerging treatments targeting brain regions involved in neuroplasticity have shown promising results. It does not report a cure or proven new treatment.
-
As rural areas have lower reported ADRD prevalence compared to urban areas in spite of lower educational attainment (which should lead to higher ADRD prevalence) this argues that the true burden of ADRD is likely underestimated in areas without adequate detection resources.
Why it matters
Appalachian counties had higher dementia prevalence than non-Appalachian counties, both overall and by rural status. The authors note that rural areas may have underestimated dementia burden because of inadequate detection resources.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Quantification of Alzheimer disease neuropathology using tissue microarrays
- Early Alzheimer’s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries
- Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
- Facets of language performance in early‐onset and late‐onset Alzheimer's disease dementia
- Association of Nonmodifiable Risk Factors With Alzheimer Disease Blood Biomarkers in Community-Dwelling Adults in the ESTHER Study
- 16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer's Post-Mortem Brain
- Cuando el Alzheimer llega antes de lo esperado: la mutación del gen PSEN1
- Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours
- The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI): Ten Years of Progress in Understanding Alzheimer's in Down Syndrome
- Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis